China Study Finds Cilostazol Better Than Aspirin After Stroke
This article was originally published in PharmAsia News
Executive Summary
Chinese researchers have determined cilostazol, an anti-clotting drug, may be safer than aspirin for some people who have had a stroke. Such patients are considered at higher risk of a cerebral hemorrhage, but the anti-platelet drug appears to have a long-term effect in low doses. The researchers' work was published online by the journal The Lancet Neurology. Cilostazol is made in China by Otsuka Pharmaceutical under the brand Pletal. (Click here for more